Results 241 to 250 of about 26,895 (263)

SGLT2 Inhibitor–Induced Sympathoinhibition

JACC Basic To Translational Science, 2020
Lakshini Y Herat, Caroline Rudnicka, Revathy Carnagarin   +2 more
exaly  

SGLT2 inhibitors

British Journal of Cardiology, 2017
openaire   +1 more source

SGLT2 inhibitors may prevent diabetes

Nature Reviews Nephrology, 2022
Daniel V. O’Hara, Meg J. Jardine
openaire   +2 more sources

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor

New England Journal of Medicine, 2017
Michael Fralick, Sebastian Schneeweiss, Elisabetta Patorno   +2 more
exaly  

SGLT2 inhibitors in clinical practice

The Lancet Diabetes & Endocrinology
Lars, Rydén, Anna, Norhammar
openaire   +2 more sources

A case in which SGLT2 inhibitor is a contributing factor to takotsubo cardiomyopathy and heart failure

Journal of Cardiology Cases, 2020
Haruyuki Kinoshita, Hiroshi Sugino, Takashi Shimonaga   +2 more
exaly  

Dapagliflozin, an SGLT2 inhibitor, for diabetes

The Lancet, 2010
Markolf, Hanefeld, Thomas, Forst
openaire   +2 more sources

SGLT2 inhibitors and cardiovascular outcomes

Drug and Therapeutics Bulletin, 2017
openaire   +2 more sources

Discovery of Ipragliflozin (ASP1941): A novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus

Bioorganic and Medicinal Chemistry, 2012
Eiji Kurosaki, Masayuki Yokota, Mitsuaki Ohta   +2 more
exaly  

Pharmacokinetics, pharmacodynamics and safety of empagliflozin, a sodium glucose cotransporter 2 ( SGLT2 ) inhibitor, in subjects with renal impairment

Diabetes, Obesity and Metabolism, 2014
M Mattheus, U C Broedl
exaly